EMEA-001912-PIP01-15
Key facts
| Active substance |
Angiotensin II (LJPC-501)
|
| Therapeutic area |
Other
|
| Decision number |
P/0253/2016
|
| PIP number |
EMEA-001912-PIP01-15
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of catecholamine-resistant hypotension associated with distributive shock
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
La Jolla Pharmaceutical Company, Inc.
United States
Tel. +1 8584336908 |
| Decision type |
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan
|